Cadence Reports Priority Review, Acceptance Of NDA Submission For Acetavance
Published: 15-Jul-2009
Acetavance is intended for the treatment of acute pain and fever
Cadence's New Drug Application (NDA) for Acetavance (intravenous acetaminophen) has been accepted for filing by the FDA, and is designated for Priority Review. The drug will be used for the treatment of acute pain and fever in adults and children.
The company said that the Priority Review designation reduces the target review period for NDA, from ten months to six months. Acceptance of the NDA submission indicates that FDA has made a threshold determination that its NDA is sufficiently complete to permit a substantive review. .
The submission includes safety data from over 1,400 patients who received Acetavance in clinical trials, including 350 pediatric patients, from premature neonates to adolescents. It also includes data from safety reports that collectively represent more than 53 million patient exposures to intravenous acetaminophen, in countries outside the US.
Ted Schroeder, president and CEO of Cadence, said: We are very pleased with the FDA's decision to grant the Acetavance NDA a Priority Review, which we believe reflects the potential of Acetavance to fulfill a significant unmet need for a new class of intravenous medication to treat acute pain and fever in adults and children, for which there remains a large gap in the US treatment paradigm.
Network Sites

Suppliers To This Sector
Browse A-Z
Solutions4Science
Temperature Mapping and Validation Services ...
Exploristics
Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...
NeuroProof
Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...
DASGIP
Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...
BioKinetic Europe
Phase I/II Contract Research Organisation ...
Toxikon Europe
CRO Providing Preclinical Safety Studies for the Life Science Community ...
White Papers
Browse A-Z
GRACO's New FDA Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New Hydra-Clean
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New 1590 & 3150 Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Customer Testimonial – Astra Zeneca
From the control room to the downstream processing area and with an eye on utilities servi ...
Hygienic Processing
From the control room to the downstream processing area and with an eye on utilities servi ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully